FDA Import Regulations and Product Detentions

The U.S. Food and Drug Administration exercises authority over a substantial share of all goods entering the United States — approximately 40 cents of every dollar spent on food consumed in the country involves an imported product, and FDA-regulated goods account for roughly 20% of all U.S. imports by value (FDA Import Program Overview). This page covers the statutory framework that governs FDA import oversight, the mechanics of how shipments are examined and detained, the most common product categories and violation scenarios that trigger enforcement, and the decision thresholds that separate refused entry from release under certain conditions. The FDA's scope across regulated product categories directly shapes how broadly these import rules apply.

Definition and Scope

FDA import authority derives primarily from the Federal Food, Drug, and Cosmetic Act (FD&C Act), codified at 21 U.S.C. § 381, which empowers the agency to refuse admission of any article that appears to violate the Act or the Public Health Service Act. This authority extends to food, drugs, medical devices, cosmetics, tobacco products, biological products, veterinary products, and radiation-emitting electronic goods.

The practical scope is expansive. FDA operates alongside U.S. Customs and Border Protection (CBP) through an integrated data system called the Automated Commercial Environment (ACE), which processes entry filings before physical goods arrive at a U.S. port. Importers of record must submit prior notice for food shipments under 21 C.F.R. Part 1, Subpart I, a requirement established under the Bioterrorism Act of 2002 and later reinforced by the FDA Food Safety Modernization Act (FSMA). Failure to submit prior notice is itself grounds for refusal.

FDA maintains a public database of import alerts — standing instructions to automatically detain shipments from specific firms, countries, or product types — at FDA Import Alerts. Import Alert 66-40, for example, covers detention without physical examination (DWPE) for seafood from firms that have demonstrated repeated HACCP violations.

How It Works

When a regulated shipment arrives, FDA and CBP evaluate the entry filing through a risk-based targeting process. The sequence operates as follows:

1. Prior notice or entry submission — The importer files documentation through ACE before or upon arrival. FDA's systems screen against import alerts, compliance history, country of origin, and product type.
2. Automatic Release or Examination Flag — Shipments with no flags are released without physical examination. Those flagged are held pending further review.
3. Notice of Examination (NOE) — If FDA decides to examine a shipment, the agency issues a formal notice. The importer may not distribute the goods during examination.
4. Sampling and Laboratory Analysis — FDA field investigators collect samples, which are tested at one of FDA's field laboratories. Results may take days to weeks depending on the type of analysis required.
5. Notice of Detention and Hearing (NODAH) — If sampling reveals apparent violations, FDA issues a NODAH under 21 C.F.R. § 1.94, giving the importer an opportunity to submit testimony or evidence within the specified period (typically not less than 10 working days).
6. Refusal or Conditional Release — After reviewing any submitted evidence, FDA either refuses admission or issues a conditional release for reconditioning under 21 U.S.C. § 381(b).
7. Exportation or Destruction — Refused goods must be exported or destroyed under CBP and FDA supervision within 90 days of the refusal notice.

Detention without physical examination (DWPE) bypasses some of this sequence: when a firm is on an active import alert, individual shipments can be detained automatically based solely on the alert listing, without FDA physically inspecting each lot.

Common Scenarios

The product categories and violation types that generate the largest share of import detentions fall into four primary clusters:

Adulterated food and seafood — Shipments detained for filth, pesticide residues above tolerance levels established by the Environmental Protection Agency under 40 C.F.R. Part 180, or unapproved drug residues in aquaculture products. FSMA's Foreign Supplier Verification Program (FSVP), detailed at 21 C.F.R. Part 1, Subpart L, requires U.S. importers to conduct risk-based supplier verification before import — failure to maintain FSVP records is a standalone violation.

Unapproved drugs and misbranded pharmaceuticals — Prescription medications imported without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), counterfeit drugs, and products with labeling that does not conform to 21 C.F.R. Part 201.

Medical devices lacking clearance or approval — Devices entering commerce without a valid 510(k) clearance or Premarket Approval (PMA), or devices manufactured under conditions that do not satisfy Quality System Regulation requirements under 21 C.F.R. Part 820.

Cosmetics with prohibited ingredients — Products containing colorants not approved for cosmetic use in the U.S., or formulations that cross into drug territory under FDA's classification framework.

Decision Boundaries

FDA's import enforcement distinguishes between two fundamentally different administrative postures:

The distinction between refusal and detention carries significant operational weight. A detained shipment is still in legal limbo — the importer retains the right to present evidence, submit a request for hearing, or arrange reconditioning. A refused shipment has received a final agency determination; the only path forward is exportation or destruction, or a formal petition challenging the decision.

Reconditioning — relabeling, reprocessing, or segregating non-violative portions — is available only for certain violation types. Adulteration based on inherent contamination (e.g., a naturally occurring toxin throughout a lot) typically cannot be remediated through reconditioning. Misbranding violations, by contrast, can often be resolved by applying compliant labeling under FDA supervision.

Firms subject to a DWPE import alert can seek removal by submitting evidence of corrective action to the responsible FDA district office, but the burden of proof rests entirely on the importer or foreign manufacturer. FDA has no statutory deadline to act on such petitions, and the process can take months to years depending on the complexity of the underlying violation history.